证券代码：300804 证券简称：广康生化 公告编号：2025-046 广东广康生化科技股份有限公司 关于特定股东减持股份的预披露公告 股东深圳市华拓至远叁号投资企业（有限合伙）、共青城华拓至盈贰号投资合 伙企业（有限合伙）保证向本公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 广东广康生化科技股份有限公司（以下简称"本公司"、"公司"或"发行人"） 的股东共青城华拓至盈贰号投资合伙企业（有限合伙）目前持有公司股份 884,400 股 （占本公司总股本比例 1.1951%）；深圳市华拓至远叁号投资企业（有限合伙）目前 持有公司股份 445,600 股（占本公司总股本比例 0.6022%）。根据《广东广康生化科 技股份有限公司首次公开发行股票并在创业板上市招股说明书》，上述股东因共同的 基金管理人（执行事务合伙人）为深圳市华拓私募股权投资基金管理有限公司，合并 计算股份比例，合并计算后上述股东合计持有公司股份 1,330,000 股（占公司总股本 比例 1.7973%）。 现上述股东计划自本公告披露日起的 ...

| 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括 但不限于防止关联方占用公司资源的制度、 | 是 | | 募集资金管理制度、内控制度、内部审计制 | | | 度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月 1 次 | | （2）公司募集资金项目进展是否与信息披露 文件一致 | 是 | | 4.公司治理督导情况 | | | （1）列席公司股东会次数 | 次 1 | | （2）列席公司董事会次数 | 次 1 | | 5.现场检查情况 | | | （1）现场检查次数 | 0 次 | | （2）现场检查报告是否按照深圳证券交易所 规定报送 | 不适用 | | （3）现场检查发现的主要问题及整改情况 | 不适用 | | 6.发表专项意见情况 | | | ...

Group 1 - Company Guangkang Biochemical announced a share reduction plan by specific shareholders, allowing them to reduce up to 2.22 million shares, which is 3% of the total share capital, from June 9, 2025, to September 8, 2025 [1] - The shareholders have completed their reduction plan, having sold a total of 2.22 million shares, representing 3% of the company's total share capital [1] - For the year 2024, Guangkang Biochemical's revenue composition is heavily weighted towards pesticides, accounting for 99.84% of total revenue, with other businesses making up only 0.16% [1] Group 2 - The current market capitalization of Guangkang Biochemical is 3.1 billion yuan [2]

证券代码：300804 证券简称：广康生化 公告编号：2025-045 广东广康生化科技股份有限公司 关于特定股东减持股份计划期限届满暨实施完毕的公告 股东深圳市华拓至远投资企业（有限合伙）、深圳市华拓至远贰号投资企业 （有限合伙）、深圳市华拓至远叁号投资企业（有限合伙）、共青城华拓至盈贰 号投资合伙企业（有限合伙）保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 广东广康生化科技股份有限公司（以下简称"公司"或"发行人"）于 2025 年 6 月 4 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于特定股东减持股份预披露 公告》（公告编号：2025-022），公司股东深圳市华拓至远投资企业（有限合伙）、 深圳市华拓至远贰号投资企业（有限合伙）、深圳市华拓至远叁号投资企业（有限合 伙）、共青城华拓至盈贰号投资合伙企业（有限合伙）计划于减持计划公告之日起三 个交易日后的三个月内（即 2025 年 6 月 9 日-2025 年 9 月 8 日）以集中竞价交易或大 宗交易方式减持公司股份累计不超过 ...

证券日报网讯广康生化（300804）8月26日在互动平台回答投资者提问时表示，公司始终以"致力于打造 卓越、安全、环保、绿色的一流农化企业"为发展愿景，在实际运营中，公司并非在盈利与社会责任间 取舍，而是致力让技术进步、绿色价值观和市场回报形成正向循环。以绿色理念指导研发，确保产品环 保与安全；以技术优势打造差异化、高附加值产品矩阵；以市场成果反哺创新投入，持续增强核心竞争 力。这一协同机制已融入公司产品布局和运营管理，确保公司在实现业绩增长的同时，切实履行环境与 社会责任。未来，公司将继续坚持以绿色创新为驱动，推动高质量、可持续发展，回馈广大投资者的信 任与支持。 ...

Core Insights - Guangkang Biochemical reported a revenue of 399 million yuan for the first half of 2025, marking a year-on-year increase of 25.55% [1] - The net profit attributable to shareholders reached 29.01 million yuan, up 32.13% year-on-year, with a significant increase of 190% in net profit after deducting non-recurring gains [1] - The company achieved a positive net cash flow from operating activities of 38.67 million yuan, reversing from a negative position in the same period last year [1] Revenue Breakdown - The revenue from the raw material business was 329 million yuan, an increase of 18.26%, accounting for 82.42% of total revenue [1] - The formulation business generated 69.05 million yuan, showing a substantial growth of 82.64% [1] - The growth in revenue is attributed to increased sales of fungicide products and expansion in the formulation business, alongside cost reduction through optimized production processes [1] R&D and Innovation - The company invested 16.70 million yuan in R&D, reflecting an 11.83% increase year-on-year [2] - Guangkang Biochemical achieved certification for the GB/T29490-2023 intellectual property compliance management system and was recognized as a provincial-level technology center [2] - The company has developed expertise in key technology areas such as chlorination and diazotization, supporting continuous product upgrades [2] Market Strategy and Product Development - The company adheres to a "differentiated and niche" competition strategy, which has proven effective [2] - Core products such as Kexingdan and Mieqingdan received a 15-year renewal approval from the EU, with usage restrictions lifted, expected to boost overseas market demand [2] - The production lines for Mieqingdan at the Yingde base are operating at full capacity, while the Kexingdan production capacity at the Shaoguan base is continuously increasing [2] Product Portfolio and International Collaboration - Guangkang Biochemical is a major supplier of succinate dehydrogenase inhibitors and trichloromethyl sulfur fungicides, with a strong product matrix including Benfluralin, Thifensulfuron, and Kexingdan [2] - The company is the sole domestic producer of Toxaphene, and its clean production processes for Kexingdan and Mieqingdan have received national invention patents [2] - The company maintains stable collaborations with multinational agrochemical firms such as UPL and ADAMA, with products distributed in major markets like the US and EU [2]

Group 1 - Guangkang Biotech (300804.SZ) released its semi-annual report for 2025 on August 22, 2025, indicating that as of August 21, 2025, a total of 8 institutional investors disclosed holdings in Guangkang Biotech A-shares, with a total holding of 10.2497 million shares, accounting for 13.85% of the total share capital [1] - The institutional investors include several firms such as Yingde Zhongxing Investment Management Co., Ltd., Shenzhen Qianhai Ruihong Kaiyin Asset Management Co., Ltd., and Morgan Stanley & Co. International PLC, among others [1] - Compared to the previous quarter, the total proportion of institutional holdings decreased by 5.09 percentage points [1] Group 2 - In the public fund sector, one public fund, CITIC Prudential Multi-Strategy Mixed (LOF) A, was not disclosed in this period compared to the previous quarter [2] - Regarding foreign investment attitudes, one new foreign institution disclosed in this period is Morgan Stanley & Co. International PLC [2]

Core Insights - Guangkang Biochemical (300804.SZ) reported a total operating revenue of 399 million yuan for the first half of 2025, an increase of 81.18 million yuan compared to the same period last year, representing a year-on-year growth of 25.55% [1] - The net profit attributable to shareholders was 29.01 million yuan, up by 7.05 million yuan from the same period last year, reflecting a year-on-year increase of 32.13% [1] - The net cash inflow from operating activities was 38.67 million yuan, an increase of 39.09 million yuan compared to the same period last year [1] Financial Metrics - The latest gross profit margin is 23.63%, an increase of 0.22 percentage points from the previous quarter and up by 0.88 percentage points year-on-year [2] - The latest return on equity (ROE) is 2.14%, an increase of 0.46 percentage points compared to the same period last year [2] - The diluted earnings per share (EPS) is 0.39 yuan, an increase of 0.09 yuan year-on-year, representing a growth of 31.18% [2] - The total asset turnover ratio is 0.19 times, an increase of 0.03 times year-on-year, reflecting a growth of 15.08% [2] - The inventory turnover ratio is 1.82 times, an increase of 0.40 times compared to the same period last year, representing a year-on-year growth of 28.46% [2] Shareholder Information - The number of shareholders is 10,800, with the top ten shareholders holding a total of 52.54 million shares, accounting for 71.00% of the total share capital [2] - The largest shareholder is Cai Danqun, holding 34.8% of the shares [2] Debt Metrics - The latest debt-to-asset ratio is 35.92% [3]

（文章来源：每日经济新闻） 广康生化（SZ 300804，收盘价：43.58元）8月21日晚间发布半年度业绩报告称，2025年上半年营业收 入约3.99亿元，同比增加25.55%；归属于上市公司股东的净利润约2901万元，同比增加32.13%；基本每 股收益0.3921元，同比增加31.18%。 ...

证券日报网讯8月21日晚间，广康生化（300804）发布公告称，公司董事会同意聘任王世银先生、车林 先生、冯维国先生为公司副总经理。 ...